종양학용 정밀 의료 제휴 및 라이선싱 계약(2016-2026년)

The definitive benchmark for precision oncology dealmaking

Precision medicine in oncology partnering is driven by biomarker-based strategies and targeted therapies, with deal structures reflecting the integration of diagnostics, data, and therapeutic development in a highly competitive environment.

This report provides a comprehensive and structured analysis of 970+ precision oncology collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how precision oncology deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by biomarker strategy, therapy type, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures across a highly competitive and biomarker-driven oncology landscape
• Full visibility into deal structure and execution
• Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections
• This level of transparency is critical to understanding how value, risk, and control are allocated within precision oncology partnerships, particularly where coordination between diagnostics, therapeutics, and clinical development strategies is essential.
• Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark precision oncology transactions
• Prepare for negotiations with well-defined market context
• Evaluate integrated diagnostic-therapeutic partnerships
• Support internal strategy with robust, defensible data
• What's included
• 970+ precision oncology collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, biomarker strategy, and therapy type)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for precision oncology dealmaking
• Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how precision oncology partnerships are structured, negotiated, and valued.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in precision medicine in oncology dealmaking

• 2.1. Introduction
• 2.2. Precision medicine in oncology deals over the years
• 2.3. Most active precision medicine in oncology dealmakers
• 2.4. Precision medicine in oncology deals by deal type
• 2.5. Precision medicine in oncology deals by therapy area
• 2.6. Precision medicine in oncology deals by industry sector
• 2.7. Deal terms for precision medicine in oncology deals
  • 2.7.1 Precision medicine in oncology deals headline values
  • 2.7.2 Precision medicine in oncology deal upfront payments
  • 2.7.3 Precision medicine in oncology deal milestone payments
  • 2.7.4 Precision medicine in oncology royalty rates

Chapter 3 - Leading precision medicine in oncology deals

• 3.1. Introduction
• 3.2. Top precision medicine in oncology deals by value

Chapter 4 - Most active precision medicine in oncology dealmakers

• 4.1. Introduction
• 4.2. Most active precision medicine in oncology dealmakers
• 4.3. Most active precision medicine in oncology deals company profiles

Chapter 5 - Precision medicine in oncology contracts dealmaking directory

• 5.1. Introduction
• 5.2. Precision medicine in oncology contracts dealmaking directory

Chapter 6 - Precision medicine in oncology dealmaking by technology type

• Deal directory
• Deal directory - Precision medicine in oncology deals by company A-Z
• Deal directory - Precision medicine in oncology deals by deal type
• Deal directory - Precision medicine in oncology deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Precision medicine in oncology deals since 2016
• Figure 2: Active precision medicine in oncology dealmaking activity since 2016
• Figure 3: Precision medicine in oncology deals by deal type since 2016
• Figure 4: Precision medicine in oncology deals by therapy area since 2016
• Figure 5: Precision medicine in oncology deals by industry sector since 2016
• Figure 6: Precision medicine in oncology deals with a headline value
• Figure 7: Precision medicine in oncology deals with an upfront value
• Figure 8: Precision medicine in oncology deals with a milestone value
• Figure 9: Precision medicine in oncology deals with a royalty rate value
• Figure 10: Top precision medicine in oncology deals by value since 2016
• Figure 11: Most active precision medicine in oncology dealmakers since 2016
• Figure 12: Precision medicine in oncology deals by technology type since 2016